<DOC>
	<DOCNO>NCT00384098</DOCNO>
	<brief_summary>Vitamin D analog currently widely use treatment psoriasis . The study drug ( CTA018 ) novel analog vitamin D , Phase 2 study investigate efficacy safety CTA018 treatment psoriasis . Patients chronic plaque psoriasis receive one three dos CTA018 cream vehicle ( study drug ) daily 12 week .</brief_summary>
	<brief_title>Safety Efficacy Topically Applied CTA018 Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>clinical diagnosis chronic plaque psoriasis 6 month max 15 % body surface area exclude face , scalp , groin , axilla , palm , sol foot least two evaluable plaque CPSS &gt; /= 6 baseline PSGA &gt; /= 2 woman childbearing potential msut agree use effective form contraception guttate , pustular , erythrodermic nonplaque form psoriasis concomitant serious illness/condition may interfere participation study use topical therapy within 2 week prior baseline visit use phototherapy systemic psoriasis therapy within 4 week prior baseline visit prolong exposure natural artificial UV radiation within 4 week baseline visit intend exposure study use systemic immunomodulatory therapy within 12 week prior baseline visit history hypercalcemia kidney stone unable unwilling discontinue calcium and/or vitamin D supplementation study pregnant nursing mother participate participate interventional study within 30 day study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>